Fierce Biotech
Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal. But the companies still plan to file the vaccine with regulators.